Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
Abstract
Clofarabine-based reduced-intensity conditioning (RIC) regimens are well-established schedules for allograft in patients with myeloid malignancies. A retrospective study was conducted including all adults allografted in our department with such a regimen and disease with the aim to assess whether or not the donor type (matched sibling [MSD], matched unrelated [MUD], or haploidentical [haplo]) impacted outcomes. Between October 2009 and February 2018, 118 patients met the inclusion criteria. Thirty-six, 55, and 27 patients received a graft from an MSD, MUD, or haplo donor, respectively. Peripheral blood stem cells (PBSCs) were the source of graft for all patients. The median age of the entire cohort was 62 years (range, 20 to 73), and the median follow-up was 31 months (range, 4.5 to 106). All patients engrafted except 1 haplo recipient. Neutrophils (>.5 × 109/L) and platelets (50 × 109/L) recoveries were significantly delayed in the haplo group (P = .0003 and P < .0001) compared with MSD and MUD. Acute grades II to IV or III to IV graft-versus-host disease (GVHD) incidences were similar between the 3 groups as well as the incidence of moderate or severe chronic GVHD. Also, similar 2-year overall survival (OS; 64.7% versus 73.9% versus 60.2%, P = .39), disease-free survival (DFS; 57.7% versus 70.9% versus and 53.6%, P = .1), and GVHD relapse-free survival (37.9% versus 54.3% versus 38.9%, P = .23) were observed between MSD versus MUD versus haplo groups. The same was true when considering only acute myeloid leukemia (AML) cases. In multivariate analysis the type of donor remained independent of outcomes in this series, whereas myelodysplastic syndrome (versus AML), high disease risk index, and older donor (≥50 years) were associated with lower OS and DFS. These data suggest that haplo donors are an acceptable alternative for patients receiving a clofarabine-based RIC PBSC allograft for myeloid malignancies who lack an MSD or a MUD.
Related
- Repurposing clofarabine against enteric pathogens via metabolic starvation
- Case Report: Low-dose donor lymphocyte infusion for secondary poor graft function after haploidentical HSCT in a child with β-thalassemia
- Kinetics of early immune reconstitution and its exploratory association with post-transplant outcomes in patients undergoing haploidentical HCT with post-transplant cyclophosphamide-based GvHD prophylaxis
- Haploidentical and MHC-identical cells exhibit broadly similar immune reconstitution kinetics, with some compartment-specific differences, following hematopoietic cell transplantation in a murine model of severe combined immunodeficiency
- Circuit plasticity coordinates action selection and temporal compression during operant conditioning in Aplysia
BibTeX
@article{bouard2026influence,
title = {{Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies}},
author = {Louise Bouard and Thierry Guillaume and Pierre Peterlin and Alice Garnier and Amandine Le Bourgeois and Alix Duquenne and Beatrice Mahe and Viviane Dubruille and Nicolas Blin and Cyrille Touzeau and Thomas Gastinne and Yannick Le Bris and Anne Lok and Antoine Bonnet and Steven Le Gouill and Philippe Moreau and Marie C Bene and Patrice Chevallier},
journal = {Biology of Blood and Marrow Transplantation},
year = {2026},
month = sep,
doi = {10.1016/j.bbmt.2019.03.025},
url = {https://nantes-universite.hal.science/hal-05745272v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
AU - Louise Bouard
AU - Thierry Guillaume
AU - Pierre Peterlin
AU - Alice Garnier
AU - Amandine Le Bourgeois
AU - Alix Duquenne
AU - Beatrice Mahe
AU - Viviane Dubruille
AU - Nicolas Blin
AU - Cyrille Touzeau
AU - Thomas Gastinne
AU - Yannick Le Bris
AU - Anne Lok
AU - Antoine Bonnet
AU - Steven Le Gouill
AU - Philippe Moreau
AU - Marie C Bene
AU - Patrice Chevallier
PY - 2026
DA - 2026/09/11
JO - Biology of Blood and Marrow Transplantation
DO - 10.1016/j.bbmt.2019.03.025
UR - https://nantes-universite.hal.science/hal-05745272v1
AB - Clofarabine-based reduced-intensity conditioning (RIC) regimens are well-established schedules for allograft in patients with myeloid malignancies. A retrospective study was conducted including all adults allografted in our department with such a regimen and disease with the aim to assess whether or not the donor type (matched sibling [MSD], matched unrelated [MUD], or haploidentical [haplo]) impacted outcomes. Between October 2009 and February 2018, 118 patients met the inclusion criteria. Thirty-six, 55, and 27 patients received a graft from an MSD, MUD, or haplo donor, respectively. Peripheral blood stem cells (PBSCs) were the source of graft for all patients. The median age of the entire cohort was 62 years (range, 20 to 73), and the median follow-up was 31 months (range, 4.5 to 106). All patients engrafted except 1 haplo recipient. Neutrophils (>.5 × 109/L) and platelets (50 × 109/L) recoveries were significantly delayed in the haplo group (P = .0003 and P < .0001) compared with MSD and MUD. Acute grades II to IV or III to IV graft-versus-host disease (GVHD) incidences were similar between the 3 groups as well as the incidence of moderate or severe chronic GVHD. Also, similar 2-year overall survival (OS; 64.7% versus 73.9% versus 60.2%, P = .39), disease-free survival (DFS; 57.7% versus 70.9% versus and 53.6%, P = .1), and GVHD relapse-free survival (37.9% versus 54.3% versus 38.9%, P = .23) were observed between MSD versus MUD versus haplo groups. The same was true when considering only acute myeloid leukemia (AML) cases. In multivariate analysis the type of donor remained independent of outcomes in this series, whereas myelodysplastic syndrome (versus AML), high disease risk index, and older donor (≥50 years) were associated with lower OS and DFS. These data suggest that haplo donors are an acceptable alternative for patients receiving a clofarabine-based RIC PBSC allograft for myeloid malignancies who lack an MSD or a MUD.
SN - 1083-8791
SN - 1523-6536
ER -